United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Conference Call July 30, 2025 9:00 AM ET
Company Participants
C.Q. Deng – Corporate Participant
Dewey Steadman – Head of Investor Relations
Gil Golden – Senior VP & Chief Medical Officer
James C. Edgemond – CFO & Treasurer
Leigh Peterson – Executive Vice President of Product Development & Xenotransplantation
Martine A. Rothblatt – Founder, Chairman & CEO
Michael I. Benkowitz – President & COO
Conference Call Participants
Andreas Argyrides – Oppenheimer & Co. Inc., Research Division
Ashwani Verma – UBS Investment Bank, Research Division
Jason Matthew Gerberry – BofA Securities, Research Division
Jessica Macomber Fye – JPMorgan Chase & Co, Research Division
Joseph John-Charles Thome – TD Cowen, Research Division
Olivia Simone Brayer – Cantor Fitzgerald & Co., Research Division
Roger Song – Jefferies LLC, Research Division
Terence C. Flynn – Morgan Stanley, Research Division
Operator
Good morning, and welcome to the United Therapeutics Corporation Second Quarter 2025 Corporate Update. My name is Steve, and I’ll be your conference operator today. [Operator Instructions] Please note, this call is being recorded.
I will now like to turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics. Please go ahead.
Dewey Steadman
Thank you, Steve, and good morning. It’s my pleasure to welcome you to the United Therapeutics Corporation’s Second Quarter 2025 Corporate Update Webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements will involve risks and uncertainties that may cause actual results to differ materially.
Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update these forward-looking statements. Today’s remarks may discuss the progress and results of clinical trials or other developments with respect to our products and these remarks are intended solely
#United #Therapeutics #Corporation #UTHR #Earnings #Call #Transcript